Physician profile
Abbas Mehdi
NPI 1356348387
$18,750.44
in general payments reported to CMS, 2019-2025
54 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,753 · 2020: $1,109 · 2021: $1,328 · 2022: $1,523 · 2023: $1,733 · 2024: $2,065 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,036 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,036.32 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $8,780.15 | 2019-2025 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $1,867.07 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $878.79 | 2020-2025 | |
| Abbvie INC. | $605.93 | 2020-2025 | |
| Genentech USA, INC. | $539.20 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Celgene Corporation | $515.38 | 2021-2025 | Zeposia |
| Ucb, INC. | $510.82 | 2019-2025 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $476.25 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $467.37 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $367.93 | 2020-2024 | Valtoco |
| Sk Life Science, INC. | $348.98 | 2020-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $281.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.57 | 2023-2025 | Hyqvia, Gammagard |
| Biogen, INC. | $220.48 | 2019-2025 | Leqembi, Skyclarys |
| Mdd US Operations, LLC | $179.36 | 2020-2025 | Gocovri, Qelbree, Gocovri |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.